Bank of New York Mellon’s Capricor Therapeutics CAPR Stock Holding History

Bank of New York Mellon’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.9M	Buy	161,767 +31,037	+24%	+$941K	﹤0.01%	2585
2026 Q1	$3.97M	Buy	130,730 +12,366	+10%	+$329K	﹤0.01%	2443
2025 Q4	$3.42M	Buy	118,364 +23,694	+25%	+$309K	﹤0.01%	2533
2025 Q3	$683K	Buy	94,670 +4,317	+5%	+$31.8K	﹤0.01%	3424
2025 Q2	$897K	Buy	90,353 +2,633	+3%	+$27.8K	﹤0.01%	3189
2025 Q1	$832K	Buy	87,720 +3,693	+4%	+$51.3K	﹤0.01%	3166
2024 Q4	$1.16M	Buy	84,027 +20,638	+33%	+$362K	﹤0.01%	3059
2024 Q3	$964K	Sell	63,389 -16,393	-21%	-$81.1K	﹤0.01%	3155
2024 Q2	$381K	Buy	79,782 +9,040	+13%	+$50.4K	﹤0.01%	3709
2024 Q1	$480K	Sell	70,742 -14,017	-17%	-$67.8K	﹤0.01%	3549
2023 Q4	$414K	Buy	84,759 +412	+0.5%	+$1.34K	﹤0.01%	3658
2023 Q3	$288K	Sell	84,347 -197	-0.2%	-$1.11K	﹤0.01%	3813
2023 Q2	$404K	Sell	84,544 -53	-0.1%	-$233	﹤0.01%	3704
2023 Q1	$357K	Hold	84,597	–	–	﹤0.01%	3670
2022 Q4	$327K	Sell	84,597 -59	-0.1%	-$282	﹤0.01%	3758
2022 Q3	$508K	Hold	84,656	–	–	﹤0.01%	3554
2022 Q2	$296K	Sell	84,656 -719	-0.8%	-$2.55K	﹤0.01%	3885
2022 Q1	$293K	Hold	85,375	–	–	﹤0.01%	4028
2021 Q4	$250K	Hold	85,375	–	–	﹤0.01%	4172
2021 Q3	$343K	Hold	85,375	–	–	﹤0.01%	3988
2021 Q2	$438K	Sell	85,375 -1,391	-2%	-$5.89K	﹤0.01%	3830
2021 Q1	$406K	Sell	86,766 -2,483	-3%	-$14.3K	﹤0.01%	3801
2020 Q4	$306K	Buy	89,249 +28,809	+48%	+$125K	﹤0.01%	3823
2020 Q3	$317K	Buy	+60,440	New	+$352K	﹤0.01%	3702
2019 Q2	–	Sell	-2,430	Closed	-$11K	–	4217
2019 Q1	$11K	Sell	2,430 -80	-3%	-$412	﹤0.01%	4192
2018 Q4	$10K	Hold	2,510	–	–	﹤0.01%	4195
2018 Q3	$26K	Hold	2,510	–	–	﹤0.01%	4193
2018 Q2	$34K	Sell	2,510 -166	-6%	-$2.26K	﹤0.01%	4133
2018 Q1	$36K	Sell	2,676 -68	-2%	-$1.18K	﹤0.01%	4213
2017 Q4	$44K	Buy	+2,744	New	+$59.4K	﹤0.01%	4218
2017 Q2	–	Sell	-1,496	Closed	-$51K	–	4302
2017 Q1	$51K	Buy	+1,496	New	+$41.5K	﹤0.01%	4133

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BDF

Black Diamond Financial Towson, Maryland $1.13B AUM 22.3% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's CAPR Position: Q2 2026 in Review

Bank of New York Mellon increased its Capricor Therapeutics (CAPR) stake by 24% in Q2 2026, buying an estimated $941K and bringing the position to 161,767 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2585.

Bank of New York Mellon first reported a position in CAPR in Q1 2017 and has held it in 31 quarters since. The position peaked at $3.97M in Q1 2026. 59 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Bank of New York Mellon held 161,767 shares of Capricor Therapeutics worth $3.9M as of Q2 2026.
Bank of New York Mellon bought 31,037 Capricor Therapeutics shares in Q2 2026, an estimated $941K.
Capricor Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2585 holding.
Bank of New York Mellon first reported a position in Capricor Therapeutics in Q1 2017 and has held it in 31 quarters since.
Bank of New York Mellon's Capricor Therapeutics position peaked at $3.97M in Q1 2026.
59 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.